Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PF-06801591 + PF-07921585 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PF-06801591 | PF06801591|PF 06801591|Sasanlimab | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | PF-06801591 (sasanlimab) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32847983). | |
| PF-07921585 | PF 07921585|PF07921585 | PF-07921585 is a fusion protein comprising an anti-PDCD1 (PD-1) IgG1 linked to an IL-12 mutein, which potentially enhances antitumor immune response (Cancer Res (2025) 85 (8_Supplement_1): 3414). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06580938 | Phase I | PF-07921585 PF-06801591 + PF-07921585 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | Terminated | USA | 0 |